Translational scientist with industry experience in the development of cancer immunotherapy and drugs for autoimmune diseases, expertise induce early translational sciences, and clinical biomarker discovery and development. Trained immunologist with a track record of publications in high-impact journals. Contributing member of the JLABS – JPAL program that pairs researchers from Janssen Pharmaceuticals with start-up companies from within the JLABS community of companies. Scientific Advisor to Infixion Bioscience since 2021, with a focus on Biomarker development for the NF1.
Taher Sathaliya, PhD
Commercial Drug Development; Biomarkers